Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

被引：1
|
作者：
Muggia, F.
Safra, T.
Borgato, L.
Gandhi, A.
Mancinc, G.
Gabizon, A.
Liebes, L.
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] IOV, Padua, Italy
[4] SZMC, Jerusalem, Israel
[5] NYU, Inst Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
    Faruk Tas
    Duygu Derin
    Nese Guney
    Adnan Aydiner
    Erkan Topuz
    International Journal of Clinical Oncology, 2008, 13 : 330 - 334
  • [42] Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
    Tas, Faruk
    Derin, Duygu
    Guney, Nese
    Aydiner, Adnan
    Topuz, Erkan
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 330 - 334
  • [43] Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer
    Chambers, Laura M.
    Pendlebury, Adam
    Rose, Peter G.
    Yao, Meng
    DeBernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 309 - 315
  • [44] Parmacokinetics (PK) of oral vinorelbine (VNR) in association with pegylated liposomal doxorubicin (PLD) in metastatic ovarian carcinoma
    Airoldi, M.
    Cattel, L.
    Milla, P.
    Passera, R.
    Pedani, F.
    Crova, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Ivanovic, Marija
    Walsh, Mark Doughty
    Caron, Whitney Paige
    Song, Gina
    Whitlow, Ann B.
    Newman, Suzanne E.
    La-Beck, Ninh My
    Kowalsky, Richard J.
    Zamboni, Beth A.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
    Monk, B. J.
    Herzog, T. J.
    Kaye, S. B.
    Krasner, C. N.
    Vermorken, J. B.
    Muggia, F.
    Pujade-Lourraine, E.
    Zintl, P.
    Parekh, T. V.
    Poveda, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] ADVERSE EVENT PROFILE BY AGE FOR VINTAFOLIDE plus PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VS PLD ALONE IN PLATINUM-RESISTANT OVARIAN CANCER
    Coleman, R.
    Bidzinski, M.
    Kutarska, E.
    Symanowski, J.
    Nguyen, B.
    Rangwala, R. A.
    Naumann, R. W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [48] Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial.
    Chinet-Charrot, P
    Joly, F
    Bourgeois, H
    Lortholary, A
    Leduc, B
    Priou, F
    Cumin, I
    Sevin, E
    Hamond, K
    Henry-Amar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 465S - 465S
  • [49] Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
    Runnebaum, Ingo B.
    Reichert, Dietmar
    Ringsdorf, Uta
    Kuther, Markus
    Hesse, Tobias
    Sehouli, Jalid
    Wimberger, Pauline
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (06) : 1185 - 1195
  • [50] The impact of five different administration intervals on the pharmacokinetics (PK) of paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) combination
    Cattel, Luigi
    Milla, Paola
    Cerutti, Eleonora
    Pedani, Fulvia
    Airoldi, Mario
    Crova, Alice
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 83
12345